Company Overview
About Epinoma
Epinoma is a San Francisco-based biotech company engineering proteins that read and write epigenetic signals — developing protein tools for earlier cancer and disease detection through liquid biopsy (blood tests that detect disease-specific epigenetic marks) and therapeutic interventions that modify epigenetic states to treat disease without permanently altering DNA sequence. A Y Combinator S21 graduate backed by George Church (Harvard genetics pioneer), seedToB, and SeaX Ventures with $125,000 raised, Epinoma achieved $1 million in revenue in 2024 with an 8-person team, targeting the $50 billion blood test development market.
Business Model & Competitive Advantage
Epinoma's protein engineering platform designs novel proteins that can read specific epigenetic modifications (DNA methylation patterns, histone modifications) and write new epigenetic states at targeted genomic locations. Epigenetic marks — chemical modifications on DNA and histones that regulate gene expression without changing DNA sequence — are increasingly recognized as disease biomarkers and therapeutic targets. For liquid biopsy diagnostics, specific methylation patterns in circulating tumor DNA can indicate cancer type and stage earlier than traditional biomarkers. For therapeutics, epigenetic editing can silence oncogenes or activate tumor suppressor genes.
Competitive Landscape 2025–2026
In 2025, Epinoma competes in the epigenomics tools and liquid biopsy diagnostics market with Illumina (ILMN, sequencing instruments), Grail (Galleri multi-cancer early detection test), Exact Sciences (Oncotype), and epigenetic therapeutics companies including Constellation Pharmaceuticals (acquired by MorphoSys/Novartis) for epigenetic diagnostics and tools. The liquid biopsy market is rapidly growing as multi-cancer early detection (MCED) tests demonstrate clinical validity — Grail's Galleri test and similar platforms are generating significant commercial adoption. Epinoma's protein engineering approach to epigenetic tools could provide both better detection biomarkers and the therapeutic editing tools that convert diagnostic findings into treatment interventions. George Church's advisory role connects Epinoma to the Harvard synthetic biology ecosystem. The 2025 strategy focuses on commercializing the protein tools for research and diagnostic applications, building partnerships with diagnostics companies developing liquid biopsy assays, and advancing the epigenetic therapeutics platform toward clinical validation.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Epinoma is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
S2
S2 is an AI-powered security platform focused on vulnerability discovery and attack surface management for enterprise security teams. The company's platform combines automated scanning, AI-powered ana
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Compare Epinoma with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Epinoma? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Epinoma Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Epinoma vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →